CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials

被引:54
|
作者
Junqueira, Daniela R. [1 ]
Zorzela, Liliane [1 ]
Golder, Susan [2 ]
Loke, Yoon [3 ]
Gagnier, Joel J. [4 ]
Julious, Steven A. [5 ]
Li, Tianjing [6 ,7 ]
Mayo-Wilson, Evan [8 ]
Pham, Ba [9 ]
Phillips, Rachel [10 ]
Santaguida, Pasqualina [11 ]
Scherer, Roberta W. [12 ]
Gotzsche, Peter C. [13 ]
Moher, David [14 ,15 ]
Ioannidis, John P. A. [16 ,17 ,18 ,19 ]
Vohra, Sunita [1 ]
机构
[1] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada
[2] Univ York, Dept Hlth Sci, York, N Yorkshire, England
[3] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England
[4] Western Univ, Dept Epidemiol & Biostat, Dept Surg, London, ON, Canada
[5] Univ Sheffield, Sch Hlth & Related Res ScHARR, Design Trials & Stat, Sheffield, S Yorkshire, England
[6] Univ Colorado, Sch Med, Colorado Sch Publ Hlth, Dept Ophthalmol, Anschutz Med Campus, Aurora, CO USA
[7] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA
[8] UNC Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA
[9] Unity Hlth Toronto, Knowledge Translat Programme, Toronto, ON, Canada
[10] Imperial Coll London, Fac Med, Sch Publ Hlth, London, England
[11] McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, Hamilton, ON, Canada
[12] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[13] Inst Sci Freedom, Horsholm, Denmark
[14] Ottawa Hosp Res Inst, Ctr Journalol, Clin Epidemiol Programme, Ottawa, ON, Canada
[15] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[16] Stanford Univ, Dept Med, Stanford, CA USA
[17] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA USA
[18] Stanford Univ, Dept Biomed Data Sci, Stanford, CA USA
[19] Stanford Univ, Dept Stat, Stanford, CA USA
来源
关键词
RUN-IN PERIODS; CLINICAL-TRIALS; ADVERSE EVENTS; SAFETY; EFFICACY; OUTCOMES; PLACEBO; ABSTRACTS; EVALUATE; PHASE-3;
D O I
10.1136/bmj-2022-073725
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Randomised controlled trials remain the reference standard for healthcare research on effects of interventions, and the need to report both benefits and harms is essential. The Consolidated Standards of Reporting Trials (the main CONSORT) statement includes one item on reporting harms (ie, all important harms or unintended effects in each group). In 2004, the CONSORT group developed the CONSORT Harms extension; however, it has not been consistently applied and needs to be updated. Here, we describe CONSORT Harms 2022, which replaces the CONSORT Harms 2004 checklist, and shows how CONSORT Harms 2022 items could be incorporated into the main CONSORT checklist. Thirteen items from the main CONSORT were modified to improve harms reporting. Three new items were added. In this article, we describe CONSORT Harms 2022 and how it was integrated into the main CONSORT checklist, and elaborate on each item relevant to complete reporting of harms in randomised controlled trials. Until future work from the CONSORT group produces an updated checklist, authors, journal reviewers, and editors of randomised controlled trials should use the integrated checklist presented in this paper.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials
    Junqueira, Daniela R.
    Zorzela, Liliane
    Golder, Susan
    Loke, Yoon
    Gagnier, Joel J.
    Julious, Steven A.
    Li, Tianjing
    Mayo-Wilson, Evan
    Pham, Ba
    Phillips, Rachel
    Santaguida, Pasqualina
    Scherer, Roberta W.
    Gotzsche, Peter C.
    Moher, David
    Ioannidis, John P. A.
    Vohra, Sunita
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2023, 158 : 149 - 165
  • [2] Better reporting of harms in randomized trials: An extension of the CONSORT statement
    Ioannidis, JPA
    Evans, SJW
    Gotzsche, PC
    O'Neill, RT
    Altman, DG
    Schulz, K
    Moher, D
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) : 781 - 788
  • [3] CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
    Moher, David
    Hopewell, Sally
    Schulz, Kenneth F.
    Montori, Victor
    Gotzsche, Peter C.
    Devereaux, P. J.
    Elbourne, Diana
    Egger, Matthias
    Altman, Douglas G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 : c869
  • [4] CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials
    Moher, David
    Hopewell, Sally
    Schulz, Kenneth F.
    Montori, Victor
    Gotzsche, Peter C.
    Devereaux, P. J.
    Elbourne, Diana
    Egger, Matthias
    Altman, Douglas G.
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2012, 10 (01) : 28 - 55
  • [5] THE REVISED CONSORT STATEMENT FOR REPORTING RANDOMIZED TRIALS: EXPLANATION AND ELABORATION
    Altman, Douglas G.
    Schulz, Kenneth F.
    Moher, David
    Egger, Matthias
    Davidoff, Frank
    Elbourne, Diana
    Tzsche, Peter C. G.
    Lang, Thomas
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2010, 6 (04) : 610 - 615
  • [6] The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
    Altman, DG
    Schulz, KF
    Moher, D
    Egger, M
    Davidoff, F
    Elbourne, D
    Gotzsche, PC
    Lang, T
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) : 663 - 694
  • [7] REVISED CONSORT STATEMENT FOR REPORTING RANDOMIZED TRIALS: EXPLANATION AND ELABORATION
    Altman, Douglas G.
    Schulz, Kenneth F.
    Moher, David
    Egger, Matthias
    Davidoff, Frank
    Elbourne, Diana
    Tzsche, Peter C. G.
    Lang, Thomas
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2011, 7 (01) : 110 - 116
  • [8] Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration
    Hemming, Karla
    Taljaard, Monica
    McKenzie, Joanne E.
    Hooper, Richard
    Copas, Andrew
    Thompson, Jennifer A.
    Dixon-Woods, Mary
    Aldcroft, Adrian
    Doussau, Adelaide
    Grayling, Michael
    Kristunas, Caroline
    Goldstein, Cory E.
    Campbell, Marion K.
    Girling, Alan
    Eldridge, Sandra
    Campbell, Mike J.
    Lilford, Richard J.
    Weijer, Charles
    Forbes, Andrew B.
    Grimshaw, Jeremy M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [9] The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
    Dimairo, Munyaradzi
    Pallmann, Philip
    Wason, James
    Todd, Susan
    Jaki, Thomas
    Julious, Steven A.
    Mander, Adrian P.
    Weir, Christopher J.
    Koenig, Franz
    Walton, Marc K.
    Nicholl, Jon P.
    Coates, Elizabeth
    Biggs, Katie
    Hamasaki, Toshimitsu
    Proschan, Michael A.
    Scott, John A.
    Ando, Yuki
    Hind, Daniel
    Altman, Douglas G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [10] The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
    Dimairo, Munyaradzi
    Pallmann, Philip
    Wason, James
    Todd, Susan
    Jaki, Thomas
    Julious, Steven A.
    Mander, Adrian P.
    Weir, Christopher J.
    Koenig, Franz
    Walton, Marc K.
    Nicholl, Jon P.
    Coates, Elizabeth
    Biggs, Katie
    Hamasaki, Toshimitsu
    Proschan, Michael A.
    Scott, John A.
    Ando, Yuki
    Hind, Daniel
    Altman, Douglas G.
    [J]. TRIALS, 2020, 21 (01)